STOCK TITAN

Nevro Corp - NVRO STOCK NEWS

Welcome to our dedicated page for Nevro news (Ticker: NVRO), a resource for investors and traders seeking the latest updates and insights on Nevro stock.

Overview

Nevro Corp (NYSE: NVRO) is a global medical device company headquartered in Redwood City, California. The company is renowned for its innovative approach in the field of neuromodulation and chronic pain management, providing advanced spinal cord stimulation (SCS) systems designed to transform patient outcomes. Nevro specializes in the development and commercialization of its flagship Senza SCS system, which uniquely delivers its proprietary 10 kHz high-frequency therapy. This evidence-based treatment is implemented through a comprehensive, integrated platform aimed at alleviating chronic pain across multiple conditions.

Technology and Innovation

Nevro’s technology centers on generating electrical impulses that modulate pain signals. The Senza system, along with the broader HFX platform, is built on groundbreaking research and clinical evidence. Its design incorporates sophisticated programming and, more recently, artificial intelligence enhancements through HFX AdaptivAI. This AI-driven component harnesses big data, precise algorithms, and extensive clinical outcomes to offer personalized, real-time pain relief. As a result, patients are empowered to control their pain management in a manner that is tailored to their individual needs, reducing reliance on generalized treatments.

Product Portfolio and Market Position

The company has established a diversified portfolio that not only focuses on conventional SCS devices but also extends into minimally invasive treatments for sacroiliac (SI) joint pain and fusion procedures. By broadening its offerings, Nevro addresses various facets of chronic pain, including back pain, painful diabetic neuropathy, and SI joint dysfunction. This strategic diversification enables Nevro to maintain a unique competitive edge in a market characterized by substantial underpenetration and evolving treatment protocols.

Patient and Physician Support

An integral part of Nevro’s approach lies in its comprehensive support services. The company provides extensive educational resources and application support via programs like HFX Coach, designed to ensure that patients receive continuous guidance throughout their therapy journey. Alongside patient-centric initiatives, Nevro offers advanced, cloud-based insights for physicians, empowering them with real-time data to optimize treatment plans and enhance overall practice management.

Global Reach and Regulatory Milestones

Nevro’s neuromodulation solutions are commercially available in major markets such as the United States, Europe, and Australia. Over the years, the company has successfully achieved key regulatory approvals, including CE Mark and FDA clearance, which attest to the safety, efficacy, and scientific rigor underlying its products. These milestones have not only reinforced Nevro’s position in the global medical device arena but have also paved the way for further market penetration and adoption of its innovative therapies.

Competitive Landscape and Differentiators

Operating in a highly competitive healthcare sector, Nevro differentiates itself through an unwavering commitment to evidence-based medicine and technological innovation. Its products are developed with the dual aim of delivering consistent pain relief while also ensuring a high quality of life for patients. The use of advanced AI, coupled with extensive clinical validation, positions Nevro as an authoritative entity in chronic pain treatment options. This unique amalgamation of rigorous clinical research, technological sophistication, and robust support services sets Nevro apart from its peers in the neuromodulation industry.

Conclusion

Nevro Corp remains dedicated to advancing chronic pain management through its cutting-edge medical devices and holistic care solutions. With a focus on developing technologies that are not only innovative but also grounded in robust clinical evidence, Nevro continues to enhance patient outcomes and redefine approaches to pain management across global markets.

Rhea-AI Summary
Nevro Corp. (NYSE: NVRO) announced its preliminary, unaudited fourth-quarter and full-year 2023 revenue results, with worldwide revenue exceeding expectations at $116.0 million for Q4 and $425.0 million for the full year. The company also announced a restructuring, including laying off 5% of its workforce, to support long-term growth and profitability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.96%
Tags
none
-
Rhea-AI Summary
Nevro Corp. (NYSE: NVRO) announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024. The company's management team will deliver a formal presentation at 8:15 am PST (11:15 am EST). A live webcast and replay of the presentation will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.15%
Tags
conferences
-
Rhea-AI Summary
Nevro Corp. (NYSE: NVRO) refinances with a $200M structured debt maturing in 2029, acquires Vyrsa Technologies, and closes a $200 million term loan credit facility. Vyrsa is projected to be accretive to Nevro in 2024 for both revenue and AEBITDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.66%
Tags
Rhea-AI Summary
Nevro Corp. (NYSE: NVRO) - Nevro Corp. announces the publication of new 24-month data from the SENZA Nonsurgical Refractory Back Pain (NSRBP) multicenter randomized controlled trial (RCT) in the Journal of Neurosurgery: Spine. The data show that patients in the high-frequency SCS arm experienced profound improvements in pain, function, and quality of life, plus reduced opioid use compared to the CMM arm at 24 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Nevro Corp. reported its third quarter 2023 financial results, with worldwide revenue of $103.9 million, a 3% growth compared to the same period last year. Painful Diabetic Neuropathy (PDN) indication sales grew 56% to approximately $20.8 million. The company provided fourth quarter revenue guidance of $108 million to $110 million and updated its full-year 2023 revenue guidance to $417 million to $419 million, representing 3% constant currency growth over 2022. The net loss from operations in the third quarter was $25.6 million, and the non-GAAP adjusted EBITDA loss was $5.8 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.53%
Tags
-
Rhea-AI Summary
Nevro Corp. to report Q3 2023 financial results on Nov 1, 2023. Conference call scheduled at 1:30 pm PT/ 4:30 pm ET. Webcast available on company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.93%
Tags
conferences earnings
Rhea-AI Summary
Nevro Corp. announces publication of data validating the health economic benefits of 10 kHz Therapy for chronic pain treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
none
-
Rhea-AI Summary
Nevro Corp. to present at Wells Fargo Healthcare Conference and Morgan Stanley Global Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.59%
Tags
conferences
-
Rhea-AI Summary
Nevro Corp. announces publication of 24-month data from SENZA Painful Diabetic Neuropathy (PDN) Randomized Controlled Trial, showing long-term efficacy of high-frequency 10 kHz SCS in treating PDN. Patients experienced durable pain relief, improved quality of life, and better sleep. Neurological symptoms also improved. The study confirms the safety and effectiveness of 10 kHz SCS as a therapy for PDN.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
none
Rhea-AI Summary
Nevro Corp. reported second quarter 2023 financial results, with worldwide revenue of $108.8 million, a 4% increase compared to the same period in 2022. Painful Diabetic Neuropathy (PDN) indication sales grew 73% to approximately $19.0 million. The company also provided third quarter revenue guidance of $95 million to $97 million and updated its full-year 2023 revenue guidance to $410 million to $415 million, representing 1% to 2% constant currency growth over 2022. Additionally, Nevro announced the appointment of Greg Siller as the new Chief Commercial Officer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.69%
Tags

FAQ

What is the current stock price of Nevro (NVRO)?

The current stock price of Nevro (NVRO) is $5.84 as of April 1, 2025.

What is the market cap of Nevro (NVRO)?

The market cap of Nevro (NVRO) is approximately 221.6M.

What is Nevro Corp's primary business?

Nevro Corp is a global medical device company specializing in neuromodulation therapies designed to manage chronic pain through advanced spinal cord stimulation systems.

Which products form the core of Nevro's portfolio?

The company’s core offerings include the Senza SCS system and the broader HFX platform, which utilize proprietary high-frequency therapy along with innovative SI joint fusion solutions.

How does Nevro's spinal cord stimulation system work?

Nevro’s system generates electrical impulses that modulate pain signals, enabling patients to experience effective and personalized pain relief as part of their comprehensive treatment journey.

In which markets are Nevro's products available?

Nevro’s therapies are available in major regions including the United States, Europe, Australia, and other global markets, following key regulatory approvals like FDA and CE Mark.

What role does technology play in Nevro's treatments?

Technology is central to Nevro’s approach; its products leverage advanced neuromodulation techniques, artificial intelligence, and big data analytics to offer personalized, effective pain management.

How does Nevro support its patients and healthcare providers?

The company offers comprehensive support services, featuring patient coaching programs and cloud-based insights, which aid physicians in optimizing treatment plans for better patient outcomes.

What differentiates Nevro from other pain management companies?

Nevro stands out due to its commitment to evidence-based therapy, innovative use of AI-driven technology, and a diversified product portfolio that addresses a range of chronic pain conditions.

What conditions do Nevro's therapies target?

Nevro’s solutions target various chronic pain conditions including back pain, painful diabetic neuropathy, and pain associated with sacroiliac joint dysfunction.
Nevro Corp

NYSE:NVRO

NVRO Rankings

NVRO Stock Data

221.59M
37.30M
2.88%
104.91%
4.81%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
REDWOOD CITY